Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 31, 2009

Genentech to Buy Lonza-Built Biologics Production Site in Singapore for $290M

  • Genentech exercised its option to buy Lonza’s new 80,000-litre large-scale mammalian biologics manufacturing facility in Singapore for $290 million up front and potentially another $70 million milestones. The plant is expected to produce bulk drug substance for Avastin, and will be merged with Genentech Singapore’s existing 1,000-liter biologics production plant, which is expected to receive FDA clearance for bulk production of Lucentis in 2010.

    Roche, which owns Genentech, said that by the end of 2009 the Singapore manufacturing facilities currently operating under the Genentech name will start operating under the Roche Singapore Technical Operations name.

    Lonza built the cell culture facility in Singapore as part of the companies’ 2006 agreement, through which Lonza paid $150 million to acquire Genentech’s mid-scale Avastin-producing mammalian biopharmaceutical plant in Porrino, Spain.

    Lonza is also building its own 80,000-liter large-scale mammalian manufacturing plant in Singapore, which is scheduled to come on-stream during 2011.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »